SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Using Cutting Edge Tech, Georgetown Team Proves Pancreatic Cancer Target
Pancreatic cancer is one of the deadliest forms of cancer. The five-year survival rate is a paltry 5-10%. The tumors are basically invisible to the immune system and rarely respond to chemotherapy or immunotherapy.
January 19, 2021
 · 
4 min read
 · 
Kate Goodwin
Drug Development
Biohaven’s Prodrug Troriluzole Strikes Out Again, This Time Against Alzheimer’s
Being studied for GAD, OCD, AD and spinocerebellar ataxia, Biohaven’s troriluzole has now struck out in 3 late-stage studies.
January 18, 2021
 · 
2 min read
 · 
Kate Goodwin
Business
Seattle Startup Chases Alzheimer’s with $23 Million Series A
Seattle startup AltPep targets amyloid deposits to treat Alzheimer’s Disease.
January 15, 2021
 · 
2 min read
 · 
Kate Goodwin
Business
Money on the Move: Companies Rake in Cash During Week of JPM2021
Biopharma companies raking in the cash with investment rounds and IPO announcements.
January 14, 2021
 · 
6 min read
 · 
Kate Goodwin
Existing Drug Combo Shows Potential for First Meth Addiction Treatment
With meth related deaths on the rise and no FDA-approved treatments, researchers are finding repurposed drugs that may help addicts stay clean.
January 14, 2021
 · 
3 min read
 · 
Kate Goodwin
Photo courtesy of Athira Pharma
Business
Female Powerhouse Pushes Athira to New Innovations for an Old Disease
As an immigrant, female, mid-30’s CEO in the biotech world, Leen Kawas is used to being told no. She’s familiar with doubts being cast on her ideas, eyebrows raised at her push for innovation and some flat out telling her it won’t work. And she’s comfortable with all of that. It’s that grit that’s gotten her to where she is now.
January 12, 2021
 · 
6 min read
 · 
Kate Goodwin
Policy
FDA Benches Immune-Boosting Cancer Therapy with Clinical Hold
Company will need to provide a new assay to satisfy FDA before commencing Phase I trials.
January 8, 2021
 · 
2 min read
 · 
Kate Goodwin
Deals
Starting the Year Dropping Cash - Two Companies Scooped Up This Week
Merck KGaA buys Amptec for mRNA tech and Chimerix acquires Oncoceutics for cancer pipeline.
January 8, 2021
 · 
2 min read
 · 
Kate Goodwin
Business
DBV Cuts 200 Jobs to Keep Fighting for Peanut Patch Approval
DBV announced official restructuring plan for keeping the company afloat.
January 7, 2021
 · 
1 min read
 · 
Kate Goodwin
BioCapital
Biopharma Money on the Move: December 30 - January 5
A quick overview of the life sciences companies starting the year off bringing in cash.
January 5, 2021
 · 
3 min read
 · 
Kate Goodwin
Myovant CEO David Marek, Courtesy Myovant Sciences
Business
With FDA Approval and Pfizer Deal in Hand, Myovant Appoints New CEO
Dr. Lynn Seely bows out as Myovant pivots to commercialize new drug.
January 4, 2021
 · 
3 min read
 · 
Kate Goodwin
BioMidwest
Biopharma Money on the Move: December 16-22
A roundup of the latest biopharma companies scooping up cash through IPOs and financing rounds.
December 23, 2020
 · 
4 min read
 · 
Kate Goodwin
Orgovyx becomes the first oral treatment for prost
FDA
FDA Approves Myovant Drug Orgovyx as First-Ever Oral Hormone Therapy for Prostate Cancer
Myovant’s oral Orgovyx beat out Abbvie’s injectable Lupron in achieving medical castration levels in patients. Here is the timeline of the approval.
December 21, 2020
 · 
2 min read
 · 
Kate Goodwin
Drug Development
Hope on Hold: Promising Hemophilia B Therapy Paused by FDA
The FDA put a clinical hold on UniQure’s Phase III trial after a high-risk participant developed liver cancer.
December 21, 2020
 · 
2 min read
 · 
Kate Goodwin
Policy
Four New Drugs Keeping the FDA Busy Today
Applications include a nasal COVID-19 vaccine, an NSCLC drug, respiratory infection drug and a treatment for a chronic inflammation of the esophagus.
December 17, 2020
 · 
4 min read
 · 
Kate Goodwin
Load More